1
|
Monzen H, Kubo K, Nakamura K, Uehara T, Otsuka M, Matsumoto K. The Development and Evaluation of an All-Purpose Bolus for Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e698-e699. [PMID: 37786045 DOI: 10.1016/j.ijrobp.2023.06.2181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The purpose of this study was to develop on a new bolus (HM bolus) which had tissue equivalence, transparency, reusability, and free shaping at approximately 40°C for excellent adhesion, and to evaluate its features could be satisfy ideal bolus conditions for clinical use. MATERIALS/METHODS The newly developed HM bolus was controlled to prevent phase separation by adjusting the contents of ethylene propylene rubber, styrene, butadiene rubber, thermoplastic resin, temperature-sensitive adjuster, and silica. The element ratios (wt%) in the HM bolus are H: 10.2%, C: 63.5%, O: 17.1%, and Si: 9.2%. The density was adjusted to 0.96 g cm-3. We evaluated dose characteristics, a vinyl gel sheet bolus (Gel bolus) and HM bolus placed on a water-equivalent phantom were used to obtain the percent depth dose (PDD) of electron (6 MeV, 9 MeV) and photon (4 MV,6 MV) beams. The average dose difference of the HM bolus and Gel bolus was calculated. The Gel bolus, a soft rubber bolus (SR bolus), and HM bolus were placed in adherence to a pelvic phantom. CT images taken after shaping and 1, 2, and 3 weeks after shaping were used to evaluate the adhesion and reproducibility using air gap and dice similarity coefficient (DSC) metrics. The visibility of letters (maximum: 80 pt, minimum: 10 pt) through a plate-shaped bolus and the visibility of markers when each bolus was set up on the pelvic phantom under normal room lighting were evaluated. RESULTS The average dose difference for electron beams was 0.16% ± 0.79% and photon beams was 0.06% ± 0.34%, both within 1% of the PDD results. The HM bolus showed the same build-up effect and dose characteristics as the Gel bolus. The mean air gap values for the Gel bolus, SR bolus, and HM bolus were 96.02 ± 43.77 cm3, 34.93 ± 21.44 cm3, and 4.40 ± 1.50 cm3 44, respectively. The mean DSC values for the Gel bolus, SR bolus, and HM bolus were 0.363 ± 0.035, 0.556 ± 0.042, and 0.837±0.018. The HM bolus showed the smallest air gap at all time points and the DSC closest to 1. Excellent adhesion was observed in the CT simulation and during the treatment period. The letter visibility through the HM bolus and Gel bolus was sufficient, and when the HM bolus was set up on the pelvic phantom, the markers that were completely invisible with the SR bolus were visible. CONCLUSION We succeeded in developing an all-purpose bolus with unique characteristics for clinical use. The HM bolus had the same build-up effect and dose characteristics as a Gel bolus. Therefore, it can be used for CT simulation and dose calculation. The other advantages of the new bolus are tissue equivalence, transparency, reusability, and free shaping at approximately 40°C, providing excellent adhesion at each setup during the treatment period.
Collapse
Affiliation(s)
- H Monzen
- Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan
| | - K Kubo
- Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan
| | - K Nakamura
- Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan; Takarazuka City Hospital, Takarazuka, Hyogo, Japan
| | - T Uehara
- Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - M Otsuka
- Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan
| | - K Matsumoto
- Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan
| |
Collapse
|
2
|
Kubo K, Sakurai H, Tani H, Watanabe K, Mimura M, Uchida H. Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data. J Affect Disord 2023; 320:710-715. [PMID: 36208688 DOI: 10.1016/j.jad.2022.09.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 09/26/2022] [Accepted: 09/30/2022] [Indexed: 11/17/2022]
Abstract
BACKGROUND Predicting relapse during maintenance treatment for depression is challenging. The objective of this analysis was to investigate the association between the time taken to achieve remission in the acute phase, and the subsequent relapse rate or time to relapse using the Sequenced Treatment Alternatives to Relieve Depression dataset. METHOD Data of 1296 outpatients with nonpsychotic depression who entered a 12-month naturalistic follow-up period after achieving remission with citalopram for up to 14 weeks were analyzed. One-way analysis of variance and the Jonckheere-Terpstra trend test were performed to compare the relapse rates and days to relapse during the follow-up period among those who achieved remission at weeks 2, 4, 6, 9, 12, and 14. Remission and relapse were defined as scores of ≤5 and ≥11, respectively, on the 16-Item Quick Inventory of Depressive Symptomatology and Self-Report. RESULTS The relapse rates were significantly different among those who achieved remission each week (F(5, 1087) = 4.995, p < 0.001). The lowest and highest relapse rates were observed in those who achieved remission at weeks 4 (25.7 %) and 12 (42.4 %), respectively, with a significant difference (p = 0.006). There was also a significant negative trend between the weeks taken to achieve remission and the days to relapse (z = -6.13, p < 0.001). CONCLUSIONS Patients with depression who show a faster response to antidepressant treatment are more likely to maintain remission in the long term. This finding suggests that, to prevent relapse, close attention should be paid to patients who require a relatively long time to achieve remission.
Collapse
Affiliation(s)
- Kaoruhiko Kubo
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Hitoshi Sakurai
- Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan.
| | - Hideaki Tani
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Koichiro Watanabe
- Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan
| | - Masaru Mimura
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - Hiroyuki Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
| |
Collapse
|
3
|
Nishibuchi I, Murakami Y, Miyoshi S, Kubo K, Katsuta T, Imano N, Nagata Y. Usefulness of the G8 Screening Tool in Determining Treatment Strategies for Definitive Radiotherapy of Esophageal Cancer in the Elderly. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Sugihara T, Ishizaki T, Baba H, Matsumoto T, Kubo K, Kamiya M, Hirano F, Hosoya T, Kojima M, Miyasaka N, Harigai M. POS0522 ASSOCIATED FACTORS WITH PHYSICAL DYSFUNCTION OF ELDERLY-ONSET RHEUMATOID ARTHRITIS TREATED WITH A TREAT-TO-TARGET STRATEGY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAchievement of normal physical function is an important outcome for older patients. Previous studies of younger cohorts showed that aging, comorbidities, and joint damage influenced the physical function of patients with RA who achieved clinical remission or low disease activity (LDA). We previously demonstrated that a treat-to-target (T2T) strategy for methotrexate (MTX)-naïve elderly-onset RA (EORA) was effective with an acceptable safety profile. It showed that 60.9% of 197 patients achieved HAQ Disability Index (HAQ-DI) ≤0.5 at three years by following the T2T strategy targeting LDA (1).ObjectivesWe aimed to evaluate associated factors with HAQ-DI in the T2T strategy targeting LDA for patients with EORA during three-year observational period.MethodsTreatment was adjusted to target LDA with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs (bDMARDs) in 197 MTX-naïve EORA patients (mean age 74.9 years) with moderate-to-high disease activity. HAQ-DI was evaluated at week 0, 24, 52, 76, 104, 128, and 156. To evaluate associated factors with SDAI and HAQ-DI over the 36-month follow-up, Bayesian hierarchical logistic regression modeling was applied for 1067 periods from the 197 patients.ResultsAt baseline, the enrolled 197 patients with EORA who had normal physical function (HAQ-DI ≤0.5) in 29.4%, HAQ-DI >0.5 and <1.5 in 36.5%, and HAQ-DI ≥1.5 in 33.0%, and the mean age (standard deviation [SD]) in each group was 72.7 (5.9), 74.8 (7.3), and 75.6 (6.7), respectively. Baseline SDAI increased in the group with higher HAQ-DI. The proportions of patients with each comorbidity and estimated creatinine clearance at baseline were not significantly different across the 3 groups.In the multilevel logistic model, the association of MTX, bDMARDs, and GC use with changes in SDAI in each period was evaluated. Age, sex, and comorbidities (chronic lung disease, cardiovascular disease, history of malignancy, osteoporosis, history of serious infections, and osteoarthritis) were included as inter-individual factors. The model indicated that the use of bDMARDs was associated with a reduction of the SDAI (ΔSDAI: -9.75, SD 0.75, p<0.001), while neither MTX (ΔSDAI: -1.25, SD 1.13, p=0.270) nor GCs (ΔSDAI: -0.78, SD 0.88, p=0.372) was associated with changes in SDAI. Chronic lung diseases (ΔSDAI: 4.64, SD 1.44, p=0.001) and osteoporosis (ΔSDAI: 3.78, SD 1.46, p=0.001) at baseline were associated with the increment of SDAI.The association of age, sex, the comorbidities, and MTX, bDMARDs, and GC use with physical function in each period was evaluated by the multilevel logistic model. The model indicated that older age (ΔHAQ-DI: 0.03, SD 0.01, p <0.001), chronic lung diseases (ΔHAQ-DI: 0.15, SD 0.10, p=0.001), and osteoporosis (ΔHAQ-DI: 0.30, SD 0.10, p=0.010) at baseline were associated with the increment of HAQ-DI. When the mean SDAI during the observation period was added to the model as an inter-individual factor, the associations of HAQ-DI with the chronic lung diseases and osteoporosis at baseline were not statistically significant.ConclusionThese data indicate that bDMARDs had a central role in reducing disease activity in the T2T strategy targeting LDA in EORA patients. Chronic lung diseases and osteoporosis at baseline were associated with increase in disease activity and worsening of physical function. However, disease activity had a greater impact on physical function than the comorbidities at baseline.References[1]Sugihara T, et al. Rheumatology (Oxford). 2021;60(9):4252-4261Disclosure of Intereststakahiko sugihara Speakers bureau: TS has received honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd., Grant/research support from: TS has received research grants from AsahiKASEI Co., Ltd., Daiichi Sankyo., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical., Tatsuro Ishizaki: None declared, Hiroyuki Baba: None declared, Takumi Matsumoto: None declared, Kanae Kubo Speakers bureau: KK has received honoraria from Asahi KASEI, Astellas Pharma, Bristol Myers Squibb, Eisai, AbbVie GK, Boehringer Ingelheim, Daiichi-Sankyo, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma and Nippon Shinyaku., Grant/research support from: KK has received research grants from Asahi KASEI, Mari Kamiya: None declared, Fumio Hirano: None declared, Tadashi Hosoya: None declared, Masayo Kojima Speakers bureau: MK has received speakers bureau from AbbVie, Astellas, Ayumi Pharma, Chugai, Eisai, Eli Lilly, Janssen, Ono Pharmaceutical, Pfizer, Tanabe-Mitsubishi, and Takeda Pharmaceutical Co., Ltd., Nobuyuki Miyasaka: None declared, Masayoshi Harigai Speakers bureau: MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc.,Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Consultant of: MH is a consultant for AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co.,Ltd. and Teijin Pharma., Grant/research support from: MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc.,Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.
Collapse
|
5
|
Kobayashi K, Yamashita K, Mizuno S, Kubo K, Komiya N, Otsu S. External validation of a clinical prediction rule on the need for radiologic imaging to identify urological disorders in adult patients with febrile urinary tract infections. Singapore Med J 2022; 63:167-169. [DOI: 10.11622/smedj.2022047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
6
|
Imano N, Kimura T, Kawahara D, Kubo K, Takeuchi Y, Saito A, Nishibuchi I, Murakami Y, Nagata Y. Potential Benefits of Volumetric Modulated Arc Therapy to Reduce the Incidence of Grade 2 Radiation Pneumonitis in Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Hattori T, Sugita Y, Isomura M, Kawai R, Yoshida W, Suzumura T, Suzumura Y, Kubo K, Maeda H. EFFECTS OF LOW-LEVEL LASER IRRADIATION ON THE GROWTH OF THE RAT MANDIBULAR CONDYLE IN ORGAN CULTURE. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Maeda H, Isomura M, Hattori T, Kawai R, Yoshida W, Suzumura T, Suzumura Y, Sugita Y, Kubo K. MELANOCYTES IN ODONTOGENIC CYSTS. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Kubo K, Kenjo M, Doi Y, Nakao M, Miura H, Ozawa S, Nagata Y. Interfraction Tumor Change During Stereotactic Radiotherapy For Large Brain Metastases And Importance Of Treatment Plan Modification During Treatment Period. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Nakano M, Kubo K, Shirota Y, Iwasaki Y, Takahashi Y, Igari T, Inaba Y, Takeshima Y, Tateishi S, Yamashita H, Miyazaki M, Sato H, Kanda H, Kaneko H, Ishii T, Fujio K, Tanaka N, Mimori A. Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan. Lupus 2019; 28:1062-1073. [PMID: 31296139 PMCID: PMC6681441 DOI: 10.1177/0961203319860200] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Objective The objective of this study was to investigate possible differences in
treatment responses between two categories for the onset of lupus
nephritis. Methods We performed a multicentre, retrospective cohort study of class III–V lupus
nephritis patients diagnosed between 1997 and 2014. The renal responses to
initial induction therapy were compared between patients who developed lupus
nephritis within one year from diagnosis of systemic lupus erythematosus
(early (E-) LN) and the remainder (delayed (D-) LN) using the Kaplan–Meier
method. We determined the predictors of renal response as well as renal
flares and long-term renal outcomes using multivariate Cox regression
analyses. Results A total of 107 E-LN and 70 D-LN patients were followed up for a median of
10.2 years. Log-rank tests showed a lower cumulative incidence of complete
response in D-LN compared with E-LN patients. Multivariate analysis
identified D-LN (hazard ratio (HR) 0.48, 95% confidence interval (CI)
0.33–0.70), nephrotic syndrome at baseline, and a chronicity index greater
than 2 as negative predictors of complete response. D-LN patients were more
likely to experience renal flares. D-LN (HR 2.54, 95% CI 1.10–5.83) and
decreased renal function were significant predictors of chronic kidney
disease at baseline. Conclusion D-LN was a predictor of poorer treatment outcomes, in addition to renal
histology and severity of nephritis at lupus nephritis onset.
Collapse
Affiliation(s)
- M Nakano
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan.,2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Kubo
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Shirota
- 3 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Iwasaki
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Takahashi
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Igari
- 4 Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Inaba
- 5 Biostatistics Section, Department of Clinical Research and Informatics, Clinical Science Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Takeshima
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,6 Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - S Tateishi
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,7 Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Yamashita
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Miyazaki
- 8 Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - H Sato
- 9 Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan
| | - H Kanda
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,7 Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Kaneko
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Ishii
- 3 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.,10 Clinical Research, Innovation and Educational Center, Tohoku University Hospital, Sendai, Japan
| | - K Fujio
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - N Tanaka
- 5 Biostatistics Section, Department of Clinical Research and Informatics, Clinical Science Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - A Mimori
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
11
|
Tozuka K, Nagai SE, Matsumoto H, Hayashi Y, Kubo K, Tsuboi M, Sato A, Takai K, Wang X, Yamada Y, Inoue K. Abstract P5-12-17: Prognostic and predictive value of serum level of vascular endothelial growth factor-A in metastatic breast cancer patients treated with bevacizumab plus paclitaxel. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Several studies showed that first-line bevacizumab plus chemotherapy for HER2-negative metastatic breast cancer improves progression-free survival and tumor response rate but not overall survival. MERiDiAN trial evaluated plasma vascular endothelial growth factor-A (VEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic breast cancer. However, results of this trial do not support using baseline plasma VEGF-A to identify patients benefitting most from bevacizumab. We measured baseline serum VEGF-A level from stored blood samples of metastatic breast cancer patient with treated bevacizumab plus paclitaxel as fist-line and later line therapy, and evaluated a correlation between serum VEGF-A level and efficacy of bevacizumab and prognosis of breast cancer patients tread with bevacizumab, retrospectively.
Patients and methods
We examined blood samples from 57 metastatic breast cancer patients treated with bevacizumab and paclitaxel, after obtaining written informed consent. And, we evaluated a correlation between baseline serum VEGF-A level and time to treatment failure (TTF) and overall survival (OS). We also compared the serum VEGF-A level of response group (CR and PR) and that of non-response group (SD and PD).
Results
Baseline serum level of VEGF-A ranged from 80 to 2079 pg/ml. Cases of treatment line were as follows: first-line, 22 cases (38.6%); second line, 11 cases (19.3%) and third-line and the later line, 24 cases (42.1%). The cutoff identified by ROC curve analysis that was able to differentiate response group and non-response group in first-line setting was 360pg/ml for serum VEGF-A. And, we separated high serum VGEF-A group and low serum VEGF-A group of patients treated with bevacizumab plus paclitaxel.
In patients treated as first line therapy, median TTF was 4.0 months with high serum VGEF-A group versus 5.0 months with low serum VEGF-A group, and median OS was 12 months with high serum VGEF-A group versus 11months with low serum VEGF-A group. There were no significant differences in both TTF and OS in first line setting. In patients treated as second line and later line therapy, median TTF was 2.8 months with high serum VGEF-A group versus 7.1 months with low serum VEGF-A group, and median OS was 6.4 months with high serum VGEF-A group versus 12.7 months with low serum VEGF-A group. The prognosis of high serum VEGF-A group was significantly worse than that of low serum group in both TTF and OS.
The serum VEGF-A level of response group was tend to be higher than that of non-response group in first line setting, and was lower in second and later line setting. However, there were no significant differences.
Conclusion
In this study, serum VEGF-A cannot be a predictor for efficacy of bevacizumab plus paclitaxel as first line therapy for metastatic breast cancer patients. On the other hand, there was a possibility that high serum level of VEGF-A can be a poor prognostic factor in late line therapy setting of bevacizumab.
Citation Format: Tozuka K, Nagai SE, Matsumoto H, Hayashi Y, Kubo K, Tsuboi M, Sato A, Takai K, Wang X, Yamada Y, Inoue K. Prognostic and predictive value of serum level of vascular endothelial growth factor-A in metastatic breast cancer patients treated with bevacizumab plus paclitaxel [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-17.
Collapse
Affiliation(s)
- K Tozuka
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - SE Nagai
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - H Matsumoto
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - Y Hayashi
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - K Kubo
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - M Tsuboi
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - A Sato
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - K Takai
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - X Wang
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - Y Yamada
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| | - K Inoue
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-Ken, Japan
| |
Collapse
|
12
|
Kubo K, Fleischhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs. Acta Psychiatr Scand 2019; 139:108-116. [PMID: 30198163 DOI: 10.1111/acps.12960] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/20/2018] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To examine characteristics of placebo responders and seek optimal criteria of early improvement with placebo for predicting subsequent placebo response in patients with schizophrenia. METHOD Data of 672 patients with schizophrenia randomized to placebo in nine double-blind antipsychotic trials were analyzed. Multiple logistic regression analyses were conducted to examine associations between placebo response at week 6 (i.e., a ≥ 25% reduction in the Positive and Negative Syndrome Scale [PANSS] score) and gender, age, study locations, baseline PANSS total or Marder 5-Factor scores, and per cent PANSS score reduction at week 1. Predictive power of improvement at week 1 for subsequent response was investigated; sensitivity and specificity of incremental 5% cutoff points between 5% and 25% reduction in the PANSS total score at week 1 were calculated. RESULTS Per cent PANSS total score reduction at week 1 and lower PANSS Marder disorganized thought scores at baseline were significantly associated with subsequent placebo response. A 10% reduction in a per-protocol analysis or a 15% reduction in last-observation-carried-forward analysis in the PANSS total score at week 1 showed the highest predictive power. CONCLUSION These findings are informative to identify potential placebo responders at the earliest opportunity for optimal trial design for schizophrenia.
Collapse
Affiliation(s)
- K Kubo
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - W W Fleischhacker
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.,Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria
| | - T Suzuki
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.,Department of Neuropsychiatry and Clinical Ethics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
| | - N Yasui-Furukori
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| | - M Mimura
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - H Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.,Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada
| |
Collapse
|
13
|
Strasser P, Abe M, Aoki M, Choi S, Fukao Y, Higashi Y, Higuchi T, Iinuma H, Ikedo Y, Ishida K, Ito T, Ito TU, Iwasaki M, Kadono R, Kamigaito O, Kanda S, Kawagoe K, Kawall D, Kawamura N, Kitaguchi M, Koda A, Kojima KM, Kubo K, Matama M, Matsuda Y, Matsudate Y, Mibe T, Miyake Y, Mizutani T, Nagamine K, Nishimura S, Ogitsu T, Saito N, Sasaki K, Seo S, Shimizu HM, Shimomura K, Suehara T, Tajima M, Tanaka KS, Tanaka T, Tojo J, Tomono D, Torii HA, Torikai E, Toyoda A, Tsutsumi Y, Ueno K, Ueno Y, Yagi D, Yamamoto A, Yamanaka T, Yamazaki T, Yasuda H, Yoshida M, Yoshioka T. New precise measurements of muonium hyperfine structure at J-PARC MUSE. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201919800003] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
High precision measurements of the ground state hyperfine structure (HFS) of muonium is a stringent tool for testing bound-state quantum electrodynamics (QED) theory, determining fundamental constants of the muon magnetic moment and mass, and searches for new physics. Muonium is the most suitable system to test QED because both theoretical and experimental values can be precisely determined. Previous measurements were performed decades ago at LAMPF with uncertainties mostly dominated by statistical errors. At the J-PARC Muon Science Facility (MUSE), the MuSEUM collaboration is planning complementary measurements of muonium HFS both at zero and high magnetic field. The new high-intensity muon beam that will soon be available at H-Line will provide an opportunity to improve the precision of these measurements by one order of magnitude. An overview of the different aspects of these new muonium HFS measurements, the current status of the preparation for high-field measurements, and the latest results at zero field are presented.
Collapse
|
14
|
Akizawa T, Koshikawa S, Takaku F, Urabe A, Akiyama N, Mimura N, Otsubo O, Nihei H, Suzuki Y, Kawaguchi Y, Ota K, Kubo K, Marumo F, Maeda T. Clinical Effect of Recombinant Human Erythropoietin on Anemia Associated with Chronic Renal Failure. A Multiinstitutional Study in Japan. Int J Artif Organs 2018. [DOI: 10.1177/039139888801100507] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Clinical effect and safety of recombinant human erythropoietin (r-HuEPO) were evaluated in 66 hemodialysis patients with intractable anemia. Initially, 50U/kg dry weight (DW) of r-HuEPO was administered intravenously at the end of every hemodialysis procedure for 4 weeks, then the dosage was increased to 100 and 200U/kg DW for poor responders. The patients’ hematocrits rose from 19.8 ± 2.3% (pretreatment) to 30.2 ± 4.9% after 12 weeks. From 206 U of blood transfusion requirement in the 3-month period before the study, only 34 U were needed after treatment. Serum iron and ferritin levels fell significantly during the study, and iron storage was considered to be one of the decisive factors in the response to r-HuEPO. Blood pressure rose in the course of r-HuEPO administration, but uncontrollable hypertension was rarely observed. There was no significant adverse effect of r-HuEPO except for this mild hypertension. These results indicate that r-HuEPO is an excellent therapeutic aid for the anemia associated with chronic renal failure.
Collapse
Affiliation(s)
- T. Akizawa
- Fujigaoka Hospital, Showa University Yokohama - Japan
| | - S. Koshikawa
- Fujigaoka Hospital, Showa University Yokohama - Japan
| | | | | | | | | | | | | | | | | | - K. Ota
- Tokyo Women's Medical College, Tokyo
| | - K. Kubo
- Tokyo Women's Medical College, Tokyo
| | | | - T. Maeda
- Kanto Rosai Hospital, Kawasaki - Japan
| |
Collapse
|
15
|
Tozuka K, Nagai SE, Kubo K, Komatsu K, Takai K, Inoue K, Matsumoto H, Hayashi Y, Tsuboi M, Yamada Y, Wang X, Suganuma M. Abstract P2-01-08: Enumeration of heterogeneous circulating tumor cells (CTCs) using size-based method in early, and metastatic, breast cancer patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The detection of circulating tumor cells (CTCs) in peripheral blood is an independent predictor of the efficacy of systemic therapy, and also a prognostic marker for patients with metastatic breast cancer. One of the main methods to detect CTCs is CellSearch system, which uses immune-magnetic separation followed by immunocytochemistry. A microdevice (CTChip from ClearCell system) can capture and enumerate CTCs based on distinctive physiological differences (size and deformability) between cancer cells and blood cells. CTChip thus obtains a larger CTC yield than affinity-based separation, which enriches a particular subgroup of cells expressing EpCAM. In this study, we enumerate CTCs in peripheral blood from early and metastatic breast cancer patients using a size-based method.
Patients and methods
We examined blood samples from a total of 18 early and metastatic breast cancer patients, after obtaining written informed consent. Blood samples were taken in sodium EDTA tubes after discarding the first 1ml of blood from the syringe. Two ml blood samples were applied to CTChip (ClearCell system), and CTCs were eventually trapped in the microwells of the CTChip. Trapped cells were analyzed by immunocytochemistry with monoclonal antibodies specific for leukocytes (CD45) and epithelial cells (CK8/18), along with 4',6-diamidino-2-phenylindole (DAPI) for nuclei: CK8/18-positive, DAPI-positive and CD45-negative cells more than 10 μm in diameter were defined as CTCs. Eight patients were examined using both the CTChip and CellSearch system to compare the yield of CTCs.
Results
Of 18 patients, 6 were de novo stage IV, 6 were recurrent and 6 were early stage breast cancer patients. Of primary tumors, 8 were HER2- and ER and/or PR +, 6 were HER2-and ER- and PR-, 3 were HER2+ and ER and/or PR +, and one was HER2+ and ER- and PR-. Using CTChip, detected CTCs ranged from 3 - 107 cells/2 ml in all cases: 3 - 83 for early stage, 19 - 156 for stage IV and 21 - 146 for recurrent. The number of CTCs found in recurrent patients tended to be higher than in early stage patients. Size-based method using CTChip clearly showed high sensitivity compared with the CellSearch system, which detected CTCs in only 2 cases out of 8. In analysis by immunochemistry, we found CK-negative, CD45-negative and DAPI positive cells with larger diameter (>16 μm) than CK-positive CTCs in most patients, and the numbers were higher in stage IV (8.5 cells of median value) and recurrent (13 cells) patients than in early stage patients (1.5 cells). Our study suggested that CK-negative large cells might be CTCs with epithelial–mesenchymal transition (EMT).
Conclusion
This size-based technology enables us to capture CTCs regardless of EpCAM expression. Enumerated CTCs varied in size and positivity of CK8/18, suggesting the heterogeneity of CTCs. Further research, especially focusing on EMT will be crucial to understand the key mechanism of metastasis and drug resistance.
Citation Format: Tozuka K, Nagai SE, Kubo K, Komatsu K, Takai K, Inoue K, Matsumoto H, Hayashi Y, Tsuboi M, Yamada Y, Wang X, Suganuma M. Enumeration of heterogeneous circulating tumor cells (CTCs) using size-based method in early, and metastatic, breast cancer patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-01-08.
Collapse
Affiliation(s)
- K Tozuka
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - SE Nagai
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - K Kubo
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - K Komatsu
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - K Takai
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - K Inoue
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - H Matsumoto
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - Y Hayashi
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - M Tsuboi
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - Y Yamada
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - X Wang
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| | - M Suganuma
- Saitama Cancer Center, Ina, Kita-adachi-gun, Saitama-ken, Japan; Graduate School of Science and Engineerring, Saitama University, Saitama, Saitama-ken, Japan
| |
Collapse
|
16
|
Kubo K, Hamahata A, Tozuka K, Tsuboi M, Hayashi Y, Takai K, Saito T, Sakurai H, Matsumoto H. Abstract P4-13-11: A complication analysis between complete and partial tissue expander coverage using autologous flaps in cases of immediate breast reconstruction. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-13-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
To avoid tissue expander exposure following mastectomy flap necrosis, several methods for covering expander by autologous flap in cases of immediate breast reconstruction have been reported. These methods are classified into two groups, complete or partial expander coverage. Two methods have potential risks of postoperative complications following: insufficient lower pole expansion and cranial migration in complete coverage methods, and lateral migration in partial coverage methods. However, the comparisons of complication rates between these two methods have not been reported. This study aims to compare the incidence of expander exposure following mastectomy flap necrosis and expander migration between two methods.
Methods:
A retrospective review of 93 patients (99 breasts) who underwent immediate expander-based breast reconstruction was performed. Patients were divided into two groups, complete or partial expander coverage by autologous flaps. In both groups, expanders were placed into subpectral position. In partial coverage group, the lateral borders of pectralis major muscles were sutured to the mastectomy skin flaps. If the skin flap was too thin to be sutured, the serratus anterior muscro-fascial flap was dissected and sutured to the lateral border of pectralis major muscle to cover the expander completely. Allograft products were not used in both groups. Demographics, intraoperative findings, and postoperative complications were compared between two groups.
Results:
Of the 99 breasts, 56 underwent complete expander coverage and 43 underwent partial coverage. Mastectomy flap necrosis rate was higher in the complete coverage group (Complete 14.3% versus Partial 0%; p=0.0091), however, there was no incidence of expander exposure in both groups. Lateral migration rate was higher in the partial coverage group (Complete 0% versus Partial 9.3%; p=0.033). There was no difference in cranial migration rate between two groups (Complete 12.5% versus Partial 2.3%; p=0.133).
Conclusions:
The thinness of the mastectomy flaps was considered to provide the higher incidence of mastectomy flap necrosis in the complete coverage group. The complete expander coverage reduced lateral migration rate and prevented expander exposure in cases of mastectomy flap necrosis.
Citation Format: Kubo K, Hamahata A, Tozuka K, Tsuboi M, Hayashi Y, Takai K, Saito T, Sakurai H, Matsumoto H. A complication analysis between complete and partial tissue expander coverage using autologous flaps in cases of immediate breast reconstruction [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-11.
Collapse
Affiliation(s)
- K Kubo
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - A Hamahata
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - K Tozuka
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - M Tsuboi
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - Y Hayashi
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - K Takai
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - T Saito
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - H Sakurai
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| | - H Matsumoto
- Saitama Cancer Center, 780 Komuro, Ina, Kita-Adachi, Saitama, Japan; Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
| |
Collapse
|
17
|
Kubo K, Kimura T, Aikata H, Takahashi S, Takeuchi Y, Takahashi I, Nishibuchi I, Murakami Y, Chayama K, Nagata Y. Long-Term Results of Stereotactic Body Radiation Therapy for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Kimura T, Hioki K, Aikata H, Kubo K, Takahashi S, Takeuchi Y, Takahashi I, Nishibuchi I, Murakami Y, Chayama K, Nagata Y. Repeated Stereotactic Body Radiotherapy for Intra-Hepatic Recurrent Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.989] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Honda H, Kubo K, Yamamoto R, Ishii Y, Kanzaki H, Hamamoto Y, Mochizuki T, Oita M, Sasaki M, Tominaga M, Uto Y. EP-1474: Feasibility of dose delivery error detection by a transmission detector for patient-specific QA. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31909-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT. Bone Marrow Transplant 2016; 52:252-257. [PMID: 27869808 DOI: 10.1038/bmt.2016.247] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 07/15/2016] [Accepted: 08/11/2016] [Indexed: 01/08/2023]
Abstract
A nationwide retrospective study for the clinical outcomes of 99 patients who had received thymoglobulin at a median total dose of 2.5 mg/kg (range, 0.5-18.5 mg/kg) as a second-line treatment for steroid-resistant acute GvHD was conducted. Of the 92 evaluable patients, improvement (complete or partial response) was observed in 55 patients (60%). Multivariate analysis demonstrated that male sex and grade III and IV acute GvHD were associated with a lower improvement rate, whereas thymoglobulin dose (<2.0, 2.0-3.9 and ⩾4.0 mg/kg) was NS. Factors associated with significantly higher nonrelapse mortality included higher patient age (⩾50 years), grade IV acute GvHD, no improvement of GvHD and higher dose of thymoglobulin (hazard ratio, 2.55; 95% confidence interval, 1.34-4.85; P=0.004 for 2.0-3.9 mg/kg group and 1.79; 0.91-3.55; P=0.093 for ⩾4.0 mg/kg group). Higher dose of thymoglobulin was associated with a higher incidence of bacterial infections, CMV antigenemia and any additional infection. Taken together, low-dose thymoglobulin at a median total dose of 2.5 mg/kg provides a comparable response rate to standard-dose thymoglobulin reported previously, and <2.0 mg/kg thymoglobulin is recommended in terms of the balance between efficacy and adverse effects.
Collapse
Affiliation(s)
- M Murata
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Ikegame
- Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
| | - Y Morishita
- Department of Internal Medicine, Holy Spirit Hospital, Nagoya, Japan
| | - H Ogawa
- Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
| | - K Kaida
- Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
| | - H Nakamae
- Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan
| | - T Ikeda
- Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan
| | - T Nishida
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Inoue
- Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - T Eto
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kubo
- Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan
| | - T Sakura
- Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
| | - T Mori
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - N Uchida
- Department of Hematology, Toranomon Hospital, Tokyo, Japan
| | - T Ashida
- Division of Hematology and Rheumatology, Department of Internal Medicine, Kinki University, School of Medicine, Osakasayama, Japan
| | - Y Matsuhashi
- Department of Hematology, Kawasaki Medical School, Kurashiki, Japan
| | - Y Miyazaki
- Department of Hematology, Oita Prefectural Hospital, Oita, Japan
| | - T Ichinohe
- Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
| | - Y Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.,Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Teshima
- Department of Hematology, Hokkaido University Graduate School of Medical Science, Sapporo, Japan
| |
Collapse
|
21
|
Sone S, Kasuga T, Sakai F, Hirano H, Kubo K, Morimoto M, Takemura K, Hosoba M. Chest Imaging with Dual-Energy Subtraction Digital Tomosynthesis. Acta Radiol 2016. [DOI: 10.1177/028418519303400407] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Dual-energy subtraction digital tomosynthesis with pulsed X-ray and rapid kV switching was used to examine calcifications in pulmonary lesions. The digital tomosynthesis system used included a conventional fluororadiographic TV unit with linear tomographic capabilities, a high resolution videocamera, and an image processing unit. Low-voltage, high-voltage, and soft tissue subtracted or bone subtracted tomograms of any desired layer height were reconstructed from the image data acquired during a single tomographic swing. Calcifications, as well as their characteristics and distribution in pulmonary lesions, were clearly shown. The images also permitted discrimination of calcifications from dense fibrotic lesions. This technique was effective in demonstrating calcifications together with a solitary mass or disseminated nodules.
Collapse
|
22
|
Okubo M, Shoda H, Bannai E, Kubo K, Kanda H, Fujio K, Yamamoto K. Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid. Lupus 2016; 26:334-336. [PMID: 27416846 DOI: 10.1177/0961203316659547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M Okubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Shoda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - E Bannai
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Kubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Kanda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Fujio
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Yamamoto
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| |
Collapse
|
23
|
Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K, Mimura T. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2016; 14:288-92. [PMID: 15864915 DOI: 10.1191/0961203305lu2076oa] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Recent immunosuppressive treatments for lupus nephritis have improved renal survival rate, however, there still exists lupus nephritis refractory to these treatments. Angiotensin receptor blockers (ARBs) are known not only to decrease blood pressure but also to have an independent renoprotecting effect by interrupting renin-angiotensin system. The aim of this study was to evaluate whether ARBs have an additive effect on refractory lupus nephritis. Enrolled in this trial were twelve patients with lupus nephritis who were diagnosed by renal biopsy and remained proteinuria despite corticosteroids and/or immunosuppressive treatments. ARB, losartan or candesartan, was administered for six months. Various clinical parameters were compared before and after ARB administration. Proteinuria decreased after ARB treatment in 83% of the patients and the median amount of proteinuria significantly decreased from 2530 mg/gCr to 459 mg/gCr (P = 0.03). In addition, serum albumin and cholesterol levels were significantly improved. Systolic blood pressure significantly decreased, but none had symptoms of hypotension. The antiproteinuric effect of ARB did not correlate with the reduction of blood pressure. Interestingly, higher total complement activity levels before ARB treatment were associated with a greater reduction of proteinuria. The addition of ARB would be a safe and effective treatment for lupus nephritis with persistent proteinuria despite corticosteroids and/or immunosuppressive treatments.
Collapse
Affiliation(s)
- H Kanda
- Department of Allergy and Rheumatology, University of Tokyo, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|
24
|
Fulimoto T, Maeda H, Kubo K, Sugita Y, Nakashima T, Sato E, Tanaka Y, Madachi M, Aiba M, Kameyama Y. Enhanced Anti-tumour Effect of Cisplatin with Low-voltage Electrochemotherapy in Hamster Oral Fibrosarcoma. J Int Med Res 2016; 33:507-12. [PMID: 16222883 DOI: 10.1177/147323000503300505] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The aim of this study was to determine the effects of low-voltage electrochemotherapy with intraperitoneal cisplatin on hamster oral fibrosarcoma. Oral fibrosarcoma was transplanted sub-mucosally into the cheek pouch mucosa of 100 hamsters. After transplantation, the hamsters were randomly divided into four equal groups. These groups received no treatment (D-E-); 2 mg/kg body weight cisplatin treatment without electroporation (D+E-); electroporation without cisplatin treatment (D-E+);or 2 mg/kg body weight cisplatin treatment followed by electroporation (D+E+). Electrical pulse treatment together with cisplatin injection markedly reduced the size of the tumour, whereas cisplatin injection or electrical pulse treatment alone did not. These results clearly indicate that the anti-tumour effect of cisplatin on hamster oral fibrosarcoma was considerably potentiated or enhanced by the administration of local electrical pulses at low voltages.
Collapse
Affiliation(s)
- T Fulimoto
- Department of Pathology, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kobayashi S, Shoda H, Seri Y, Nagafuchi Y, Sasaki O, Kubo K, Fujio K, Yamamoto K. Characteristics of antisynthetase syndrome patients with hyperferritinaemia. Scand J Rheumatol 2016; 46:161-163. [DOI: 10.3109/03009742.2016.1167952] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- S Kobayashi
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Shoda
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Seri
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Nagafuchi
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - O Sasaki
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Kubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Fujio
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Yamamoto
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
26
|
Kawano A, Umekita K, Matsuda M, Kubo K, Miyauchi S, Komura M, Takajo I, Nagatomo Y, Okayama A. AB0589 Hypercoagulable State Might Be Induced by Alveolar-Endothelial Damages in Interstitial Lung Disease Associated with Polymyositis/dermatomyositis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Umekita K, Miyauchi S, Matsuda M, Kubo K, Komura M, Nomura H, Kawano A, Umeki K, Takajo I, Nagatomo Y, Frank-Bertoncelj M, Gay R, Gay S, Okayama A. AB0027 A Novel Transcription Factor NFAT5 Plays An Important Role as Critical Regulator in The Inflammatory Response of Rheumatoid Arthritis Fibroblasts Mediated via Toll-Like Receptor 4 Signaling Pathways. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Kubo K, Monzen H, Tamura M, Hirata M, Nishimura Y. EP-1752: A study of suitable conditions for stereotactic radiation therapy using VMAT for lung cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33003-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Kurozumi S, Inoue K, Matsumoto H, Hayashi Y, Tozuka K, Kubo K, Komatsu K, Takai K, Nagai SE, Oba H, Horiguchi J, Takeyoshi I, Kurosumi M. Abstract P4-14-17: Prognostic value of tumor-infiltrating lymphocytes in residual tumors after neoadjuvant chemotherapy concomitant with trastuzumab for HER2-positive breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Neoadjuvant chemotherapy (NAC) with taxanes, followed by fluorouracil, epirubicin, and cyclophosphamide (FEC), with concurrent trastuzumab is known to achieve a high pCR rate of more than 60% for HER2-positive breast cancer (BC) as well as good prognoses in those obtaining pCR. On the other hand, the prognostic significance of tumor-infiltrating lymphocytes (TILs) has recently been described in triple-negative BC. However, the prognostic and predictive values of TILs in HER2-positive BC remain unclear. In the present study, we examined the grades of TILs in pre-treatment cancer tissues and residual tumors after NAC with trastuzumab, and also investigated its predictive utility for pCR and prognostic power for HER2-positive BC.
Patients and Methods:
A total of 128 Japanese women with HER2-positive BC received either paclitaxel or docetaxel followed by FEC, with concomitant trastuzumab. The proportional grades of stromal (Str)-TILs in pre-treatment biopsy specimens and residual tumors after NAC with trastuzumab were determined as follows: low grade (0-10%), intermediate grade (10-40%), and high grade (40-90%), using the criteria of the International Working Group for TILs in BC. Analysis 1: The relationship between the grades of Str-TILs in pre-treatment tumors and pCR rates was investigated. Relapse-free survival (RFS) and cancer-specific survival (CSS) were analyzed for a correlation with pre-treatment Str-TILs. Analysis 2: Alterations in the grade of Str-TILs were examined in the residual tumors of non-pCR patients, and RFS and CSS were analyzed for a correlation with residual Str-TILs.
Results:
pCR was achieved in 83 out of the 128 patients (pCR rate, 64.8%) who received NAC with trastuzumab, and RFS was significantly better in the pCR group than in the non-pCR group (p = 0.0071). Analysis 1: The patient distribution of the Str-TILs grade in pre-treatment tumors was as follows: high: 24 (18.8%); intermediate: 38 (29.7%); and low: 66 (51.6%). pCR rates correlated with the Str-TILs grade in pre-treatment tumors: 83.3% in the high group, 71.1% in the intermediate group, and 54.5% in the low group (p = 0.026); however, the Str-TILs grade in pre-treatment tumors did not correlate with survival. Analysis 2: In 45 non-pCR patients, the distribution of the Str-TILs grade in residual tumors was as follows: high: 9 (20.0%); intermediate: 8 (17.8%); and low: 28 (62.2%), respectively. In non-pCR patients, the rate of a high Str-TILs grade was greater in residual tumors than in pre-treatment tumors (residual, 20.0%, pre-treatment, 8.9%). RFS was significantly better with a high grade than with a low grade of residual Str-TILs (p = 0.033).
Conclusions:
The status of TILs in pre-treatment tumors predicted responses to NAC concomitant with trastuzumab in HER2-positive BC. The grade of TILs was higher in residual tumors than in pre-treatment tumors, and, among non-pCR patients, the prognosis of patients with a high residual-TILs grade was better prognosis than that of patients with a low residual-TILs grade. We speculate that an examination of TILs in residual tumors after NAC with trastuzumab may be necessary for selecting patients with a good prognosis from non-pCR patients.
Citation Format: Kurozumi S, Inoue K, Matsumoto H, Hayashi Y, Tozuka K, Kubo K, Komatsu K, Takai K, Nagai SE, Oba H, Horiguchi J, Takeyoshi I, Kurosumi M. Prognostic value of tumor-infiltrating lymphocytes in residual tumors after neoadjuvant chemotherapy concomitant with trastuzumab for HER2-positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-17.
Collapse
Affiliation(s)
- S Kurozumi
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Inoue
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - H Matsumoto
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - Y Hayashi
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Tozuka
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Kubo
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Komatsu
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Takai
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - SE Nagai
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - H Oba
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - J Horiguchi
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - I Takeyoshi
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - M Kurosumi
- Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan; Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| |
Collapse
|
30
|
Kubo K, Kimura T, Sakaguchi H, Imano N, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. Computed Tomographic Appearance of Radiation Injuries in Lung After Two Prescribed Dose of 48Gy With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Imano N, Kimura T, Nishibuchi I, Nakashima T, Kubo K, Sakaguchi H, Kawabata H, Takeuchi Y, Doi Y, Okabe T, Kenjo M, Ozawa S, Murakami Y, Nagata Y. A Quantitative Index for Phase Selection in Planning of Respiratory Gating Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Takeuchi Y, Murakami Y, Kubo K, Sakaguchi H, Imano N, Kawabata H, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y, Fujita M, Konishi M. Interstitial Brachytherapy for Early-Stage Tongue Cancer: Analysis of the Long-term Treatment Results for Survival and Complications. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Umekita K, Hidaka T, Miyauchi S, Kubo K, Hashiba Y, Okayama A. AB0124 Tocilizumab is Clinically Effective and Safe for Human T-Lymphotropic Virus Type 1 Positive Patients with Rheumatoid Arthritis Who Are Not Responsive to Anti-TNF Treatment. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Kubo K. Muscle oxygenation of superficial and deep regions in knee extensor and plantar flexor muscles during repeated isometric contractions. J Sports Med Phys Fitness 2015; 55:251-257. [PMID: 24947809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The purpose of this study was to investigate changes in muscle oxygenation of knee extensor and plantar flexor muscles during repeated muscle contractions under the same condition. In addition, we compared changes in muscle oxygenation between superficial and deep regions of both muscles. METHODS Eleven healthy males participated in this study. During repeated knee extensions and plantar flexions (50 repetitions at 50% of the isometric maximum voluntary contraction for 3 s with 3 s relaxations), blood volume and oxygen saturation (StO₂) of the vastus lateralis and medial gastrocnemius muscles (superficial and deep region of each muscle) were measured using near infrared spectroscopy. RESULTS The decrement of StO₂at the end of exercises was greater in plantar flexor muscle than in knee extensor muscle (P<0.001). For both muscles, the decrement of StO₂at the end of exercises was greater in the deep region than in the superficial one (both P<0.001). CONCLUSION These results suggested that the oxygen utilization of plantar flexor muscle and deep regions of each muscle were higher than that of knee extensor muscle and superficial regions of each muscle.
Collapse
Affiliation(s)
- K Kubo
- Department of Life Science, University of Tokyo Meguro, Tokyo, Japan -
| |
Collapse
|
35
|
Abstract
Previous studies demonstrated that treatment involving eccentric training was effective in the conservative management of chronic tendinosis. However, the mechanisms for these phenomena are unknown. The purpose of this study was to compare changes in blood circulation of the tendons after the repeated concentric and eccentric contractions. 11 healthy males volunteered for this study. Subjects performed the repeated concentric (CON) and eccentric (ECC) contractions (5 sets of 10 maximal voluntary contractions) of the plantar flexors. During and after repeated contractions, oxyhemoglobin (Oxy), deoxyhemoglobin (Deoxy), total hemoglobin (THb), and oxygen saturation (StO2) of the Achilles tendons were measured using red laser lights. Oxy and THb increased during and after ECC, but not CON. Deoxy decreased during both CON and ECC. Increase in StO2 during and after ECC was greater than that during and after CON. These results suggested that changes in blood circulation of the Achilles tendon during and after repeated eccentric contractions were more remarkable than those during and after repeated concentric contractions.
Collapse
Affiliation(s)
- K Kubo
- Life Science (Sports Sciences), University of Tokyo, Tokyo, Japan
| |
Collapse
|
36
|
Xiong J, Kubo K, Noro S, Akutagawa T, Nakamura T. Supramolecular cations of (m-halogenated-anilinium)(dibenzo[18]crown-6) in Keggin [SMo12O402−] polyoxometallates. CrystEngComm 2015. [DOI: 10.1039/c4ce01988a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
37
|
Makihara H, Goto M, Watanabe H, Fukuta K, Otsuka A, Kubo K, Ogi N, Kurita K. Primary mucosa-associated lymphoid tissue lymphoma of the sublingual gland: a case report. J Oral Maxillofac Surg 2014. [DOI: 10.1016/j.joms.2014.06.297] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
38
|
Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Ohashi K, Kobayashi H, Maesako Y, Adachi S, Ichinohe T, Atsuta Y, Kanda Y. Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT. Bone Marrow Transplant 2014; 49:1187-92. [PMID: 25000457 DOI: 10.1038/bmt.2014.141] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 03/03/2014] [Accepted: 04/22/2014] [Indexed: 11/09/2022]
Abstract
In unrelated hematopoietic SCT (HSCT), HLA allele mismatch has been shown to have a significant role. To clarify the importance of HLA allele mismatch in the GVH direction in related HSCT, we retrospectively evaluated 2377 patients who received stem cells from an HLA serologically matched related donor in the GVH direction using the database of the Japan Society for Hematopoietic Cell Transplantation. The cumulative incidences of grade II-IV and grade III-IV acute GVHD in patients with an HLA allele-mismatched donor (n=133, 5.6%) were significantly higher than those in patients with an HLA allele-matched donor. Multivariate analyses showed that the presence of HLA allele mismatch was associated with increased risks of grade II-IV and grade III-IV acute GVHD. In particular, HLA-B mismatch and multiple allele mismatches were associated with an increased risk of acute GVHD. The presence of HLA allele mismatch was associated with an inferior OS owing to an increased risk of non-relapse mortality (NRM). In conclusion, the presence of HLA allele mismatch in the GVH direction in related HSCT was associated with increased risks of GVHD and NRM, which led to an inferior OS. HLA allele typing is recommended in related HSCT.
Collapse
Affiliation(s)
- S Fuji
- Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
| | - J Kanda
- Division of Hematology, Saitama Medical Center, Saitama, Japan
| | - S Kato
- Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Kanagawa, Japan
| | - K Ikegame
- Division of Hematology, Department of Internal Medicine, Hyogo Medical College, Hyogo, Japan
| | - S Morishima
- Department of Hematology, Fujita Health University School of Medicine, Nagoya, Japan
| | - T Miyamoto
- Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan
| | - M Hidaka
- Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
| | - K Kubo
- Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan
| | - K Miyamura
- Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
| | - K Ohashi
- Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan
| | - H Kobayashi
- Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan
| | - Y Maesako
- Department of Hematology, Tenri Hospital, Nara, Japan
| | - S Adachi
- Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - T Ichinohe
- Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
| | - Y Atsuta
- Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kanda
- Division of Hematology, Saitama Medical Center, Saitama, Japan
| | | |
Collapse
|
39
|
Miyauchi S, Umekita K, Kawaguchi T, Sakaguchi S, Kariya Y, Hashiba Y, Matsuda M, Kubo K, Hidaka T, Umeki K, Aratake Y, Takahashi N, Sawaguchi A, Nakatake A, Morinaga I, Morishita K, Okayama A. AB0475 Increased Plasma Lactoferrin Levels in Leukocytapheresis Therapy in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Abstract
PURPOSE Interleukin-32 (IL-32) is an inflammatory cytokine that is associated with the pathogenesis of several connective tissue diseases. We measured serum IL-32γ concentrations of systemic lupus erythematosus (SLE) patients. METHODS Serum samples were obtained from SLE patients (n = 51), and healthy controls (n = 15). Serum IL-32 concentrations were measured using ELISA. Clinical information was obtained from medical records. RESULTS Serum IL-32γ was detectable in three cases of SLE patients, whereas it was not detected in any healthy controls. Case 1: a 44-year-old female with lupus nephritis (LN) (Class II) and antiphospholipid antibody syndrome. Serum IL-32γ was 5.1 pg/ml. Case 2: a 30-year-old female with a history of diffuse proliferative LN (Class IV G (A/C)) and pulmonary hemorrhage. Serum IL-32γ was 8.9 pg/ml. Case 3: a 45-year-old female with chronic LN. Serum IL-32γ was 9.1 pg/ml. All three cases of IL-32γ-detectable patients had histories of LN and one had an active disease. In the context of LN, serum IL-32γ was detectable in 18.8% (three of 16) of SLE patients with histories of LN. CONCLUSION We suppose that IL-32γ could contribute to the pathogenesis of renal diseases in some LN patients.
Collapse
Affiliation(s)
- M Inoue
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - H Shoda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - Y Seri
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - K Kubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - H Kanda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - K Fujio
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - K Yamamoto
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
41
|
Abstract
The purpose of this study was to investigate growth changes in human plantar flexor muscle and tendons. In addition, we ascertained whether growth changes in muscle and tendon were more closely related to skeletal age than chronological age. 22 elementary school children (ESC), 19 junior high school students (JHS), and 23 young adults (ADT) men participated in this study. Maximal strain and hysteresis of tendon structures and cross-sectional area of Achilles tendon were measured using ultrasonography. In addition, skeletal age was assessed using Tanner-Whitehouse III method. Maximal strain of ESC was significantly greater than that of other groups, while no significant difference was observed between JHS and ADT. There was no difference in hysteresis among 3 groups. Relative cross-sectional area (to body mass(2/3)) of ADT was significantly smaller than that of other groups. For ESC and JHS, measured variables of muscle and tendon were significantly correlated to both chronological and skeletal ages. These results suggested that immature musculoskeletal system was protected by more extensible and larger tendon structures in ESC and only by larger tendon structures in JHS, respectively. Furthermore, there were no differences in correlation coefficient values between measured variables of muscle and tendon and chronological or skeletal ages.
Collapse
Affiliation(s)
- K Kubo
- Life Science (Sports Sciences), University of Tokyo, Japan
| | - T Teshima
- Department of Physical Education, Kokushikan University, Tokyo, Japan
| | - N Hirose
- Department of Sports Science, Waseda University, Tokyo, Japan
| | - N Tsunoda
- Department of Physical Education, Kokushikan University, Tokyo, Japan
| |
Collapse
|
42
|
White GR, Ainsworth R, Akagi T, Alabau-Gonzalvo J, Angal-Kalinin D, Araki S, Aryshev A, Bai S, Bambade P, Bett DR, Blair G, Blanch C, Blanco O, Blaskovic-Kraljevic N, Bolzon B, Boogert S, Burrows PN, Christian G, Corner L, Davis MR, Faus-Golfe A, Fukuda M, Gao J, García-Morales H, Geffroy N, Hayano H, Heo AY, Hildreth M, Honda Y, Huang JY, Hwang WH, Iwashita Y, Jang S, Jeremie A, Kamiya Y, Karataev P, Kim ES, Kim HS, Kim SH, Kim YI, Komamiya S, Kubo K, Kume T, Kuroda S, Lam B, Lekomtsev K, Liu S, Lyapin A, Marin E, Masuzawa M, McCormick D, Naito T, Nelson J, Nevay LJ, Okugi T, Omori T, Oroku M, Park H, Park YJ, Perry C, Pfingstner J, Phinney N, Rawankar A, Renier Y, Resta-López J, Ross M, Sanuki T, Schulte D, Seryi A, Shevelev M, Shimizu H, Snuverink J, Spencer C, Suehara T, Sugahara R, Takahashi T, Tanaka R, Tauchi T, Terunuma N, Tomás R, Urakawa J, Wang D, Warden M, Wendt M, Wolski A, Woodley M, Yamaguchi Y, Yamanaka T, Yan J, Yokoya K, Zimmermann F. Experimental validation of a novel compact focusing scheme for future energy-frontier linear lepton colliders. Phys Rev Lett 2014; 112:034802. [PMID: 24484144 DOI: 10.1103/physrevlett.112.034802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Indexed: 06/03/2023]
Abstract
A novel scheme for the focusing of high-energy leptons in future linear colliders was proposed in 2001 [P. Raimondi and A. Seryi, Phys. Rev. Lett. 86, 3779 (2001)]. This scheme has many advantageous properties over previously studied focusing schemes, including being significantly shorter for a given energy and having a significantly better energy bandwidth. Experimental results from the ATF2 accelerator at KEK are presented that validate the operating principle of such a scheme by demonstrating the demagnification of a 1.3 GeV electron beam down to below 65 nm in height using an energy-scaled version of the compact focusing optics designed for the ILC collider.
Collapse
Affiliation(s)
- G R White
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - R Ainsworth
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - T Akagi
- Department of Physics, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - J Alabau-Gonzalvo
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - D Angal-Kalinin
- CLRC: Daresbury Laboratory, Daresbury, Warrington, Cheshire WA4 4AD, United Kingdom
| | - S Araki
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - A Aryshev
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Bai
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences (CAS), Beijing, China
| | - P Bambade
- LAL, Universite Paris-Sud, CNRS/IN2P3, Orsay, France
| | - D R Bett
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - G Blair
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom and Science and Technology Facilities Council, Polaris House, North Star Avenue, Swindon SN2 1SZ, United Kingdom
| | - C Blanch
- Universidad de Valencia - Instituto de Física Corpuscular (IFC), Edificio Institutos de Investigación, c/ Catedrático José Beltrán, 2, E-46980 Paterna, Spain
| | - O Blanco
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland and LAL, Universite Paris-Sud, CNRS/IN2P3, Orsay, France
| | - N Blaskovic-Kraljevic
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - B Bolzon
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland and CLRC: Daresbury Laboratory, Daresbury, Warrington, Cheshire WA4 4AD, United Kingdom and Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Oxford St., Liverpool L69 3BX, United Kingdom
| | - S Boogert
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - P N Burrows
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - G Christian
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - L Corner
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - M R Davis
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - A Faus-Golfe
- Universidad de Valencia - Instituto de Física Corpuscular (IFC), Edificio Institutos de Investigación, c/ Catedrático José Beltrán, 2, E-46980 Paterna, Spain
| | - M Fukuda
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - J Gao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences (CAS), Beijing, China
| | - H García-Morales
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland and Universitat Politécnica de Catalunya, BarcelonaTech, C. Jordi Girona, 31. 08034 Barcelona, Spain
| | - N Geffroy
- LAPP-Universite de Savoie-CNRS/IN2P3, Annecy-le-Vieux, France
| | - H Hayano
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - A Y Heo
- Department of Physics, Kyungpook National University, 1370 San Kyuk-dong, Puk ku, Taegu 635, South Korea
| | - M Hildreth
- University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - Y Honda
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - J Y Huang
- Pohang Accelerator Laboratory, POSTECH (Pohang University of Science and Technology), San-31 Hyoja-dong, Pohang 790-784, South Korea
| | - W H Hwang
- Pohang Accelerator Laboratory, POSTECH (Pohang University of Science and Technology), San-31 Hyoja-dong, Pohang 790-784, South Korea
| | - Y Iwashita
- Institute for Chemical Research (ICR), Nuclear Science Research Facility, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan
| | - S Jang
- Department of Physics, Kyungpook National University, 1370 San Kyuk-dong, Puk ku, Taegu 635, South Korea
| | - A Jeremie
- LAPP-Universite de Savoie-CNRS/IN2P3, Annecy-le-Vieux, France
| | - Y Kamiya
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - P Karataev
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - E S Kim
- Department of Physics, Kyungpook National University, 1370 San Kyuk-dong, Puk ku, Taegu 635, South Korea
| | - H S Kim
- Department of Physics, Kyungpook National University, 1370 San Kyuk-dong, Puk ku, Taegu 635, South Korea
| | - S H Kim
- Pohang Accelerator Laboratory, POSTECH (Pohang University of Science and Technology), San-31 Hyoja-dong, Pohang 790-784, South Korea
| | - Y I Kim
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - S Komamiya
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - K Kubo
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - T Kume
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Kuroda
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - B Lam
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - K Lekomtsev
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Liu
- LAL, Universite Paris-Sud, CNRS/IN2P3, Orsay, France
| | - A Lyapin
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - E Marin
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - M Masuzawa
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - D McCormick
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - T Naito
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - J Nelson
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - L J Nevay
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom and John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - T Okugi
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - T Omori
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - M Oroku
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - H Park
- Department of Physics, Kyungpook National University, 1370 San Kyuk-dong, Puk ku, Taegu 635, South Korea
| | - Y J Park
- Pohang Accelerator Laboratory, POSTECH (Pohang University of Science and Technology), San-31 Hyoja-dong, Pohang 790-784, South Korea
| | - C Perry
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - J Pfingstner
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - N Phinney
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - A Rawankar
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - Y Renier
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - J Resta-López
- Universidad de Valencia - Instituto de Física Corpuscular (IFC), Edificio Institutos de Investigación, c/ Catedrático José Beltrán, 2, E-46980 Paterna, Spain
| | - M Ross
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - T Sanuki
- Tohoku University, 28 Kawauchi, Aoba-ku, Sendai, 980-8576 Japan
| | - D Schulte
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - A Seryi
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - M Shevelev
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - H Shimizu
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - J Snuverink
- John Adams Institute for Accelerator Science at Royal Holloway University of London, Egham Hill, Egham, Surrey TW20 0EX, United Kingdom
| | - C Spencer
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - T Suehara
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - R Sugahara
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - T Takahashi
- Department of Physics, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - R Tanaka
- Department of Physics, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - T Tauchi
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - N Terunuma
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - R Tomás
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - J Urakawa
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - D Wang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences (CAS), Beijing, China
| | - M Warden
- John Adams Institute for Accelerator Science at University of Oxford, Denys Wilkinson Building, Keble Road, Oxford OX1 3RH, United Kingdom
| | - M Wendt
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - A Wolski
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Oxford St., Liverpool L69 3BX, United Kingdom
| | - M Woodley
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025-7090, USA
| | - Y Yamaguchi
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - T Yamanaka
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - J Yan
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
| | - K Yokoya
- High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - F Zimmermann
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| |
Collapse
|
43
|
Yoshiike F, Koizumi T, Kitaguchi Y, Hatayama O, Yasuo M, Sasabayashi M, Wakamatsu H, Fujimoto K, Kubo K. Phase I Trial of Nedaplatin and Paclitaxel for Patients with Non-Small Cell Lung Cancer. J Chemother 2013; 17:550-4. [PMID: 16323445 DOI: 10.1179/joc.2005.17.5.550] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
A phase I study was conducted to evaluate the maximum tolerated dose and feasibility of combination with nedaplatin (NDP) and paclitaxel in patients with non-small cell lung cancer (NSCLC). Fifteen patients under 75 years old, with unresectable NSCLC who had not previously received chemotherapy or radiotherapy, with a performance status of 0-1, were enrolled. The dose escalation levels (NDP/Paclitaxel; mg/m2 day 1) were 80/150 (level 1), 80/180 (level 2), 90/180 (level 3) and repeated every 28 days. All patients receiving level 3 had dose-limiting toxicity. One patient developed grade 4 neutropenia with infection, two had incomplete recovery of neutropenia and thrombocytopenia by the 28th day after the first cycle of chemotherapy. Non-hematologic toxicities, including nephrotoxicity, nausea/vomiting, alopecia, and hypersensitivity reaction, were tolerated. Three of the 15 patients achieved partial responses. We concluded that the recommended dose was paclitaxel 180 and NDP 80 mg/m2 due to the hematologic toxicity.
Collapse
Affiliation(s)
- F Yoshiike
- First Department of Internal Medicine, Shinshu University School of Medicine, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Miyauchi S, Umekita K, Hidaka T, Hashiba Y, Kawaguchi T, Matsuda M, Kubo K, Ueno S, Kusumoto N, Takajo I, Kai Y, Nagatomo Y, Okayama A. FRI0194 Treatment with anti-tumor necrosis factor (TNF) biologics to human t-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA): a case-control study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Nakai T, Sawada A, Tanabe H, Sueoka M, Kubo K, Taniuchi S, Shiinoki T, Ishihara Y, Takayama K, Kokubo M. EP-1291: Investigation of well-balanced kV x-ray imaging conditions between skin dose and image quality using Vero4DRT. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33597-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Kurozumi S, Takei H, Inoue K, Matsumoto H, Hayashi Y, Ninomiya J, Kubo K, Tsuboi M, Nagai S, Ookubo F, Oba H, Kurosumi M, Horiguchi J, Takeyoshi I. Abstract P1-14-06: Significance of examining biomarkers of residual tumors after neoadjuvant chemotherapy using trastuzumab in combination with anthracycline and taxane in patients with primary HER2-positive breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) with taxane and FEC concurrently with trastuzumab is a potent regimen in women with HER2-positive breast cancer (BC), and several studies revealed high pCR rates in BC patients treated with this regimen. In the present study, we compared the status of biomarkers before and after NAC, and evaluated rates and patterns of discordant biomarker expression. We also evaluated differences of prognosis between patients with discordant biomarker expression and those with concordant expression.
Patients and Methods: We investigated 118 Japanese women with invasive HER2 positive BC. Patients received 12 cycles of paclitaxel or 4 cycles of docetaxel followed by 4 cycles of FEC-75 with concomitant trastuzumab for 24 weeks and were followed for ≥1 year after surgery. Of these, 27 patients with residual tumors 5 mm or larger were analyzed. HER2, ER, PgR, and Ki67 were examined in primary and residual tumors. Furthermore, recurrence-free survival (RFS) and overall survival (OS) were analyzed between patients classified based on these biomarkers.
Results: Patients with pCR after NAC (75/118; 63.5%) had significantly better RFS than non-pCR patients (median follow-up: 41 months). Residual tumors were obtained from 27 of 43 non-pCR patients and examined for immunohistochemical biomarker expression. In 14/27 non-pCR patients (51.9%), residual tumors were HER2 negative, despite being HER2 positive before NAC: HER2 score changed from 3+ to 0 or 1+ in 8/18 patients (44.4%) and from 2+ to 0 or 1+ in 6/9 (66.7%). ER expression changed in 2 patients (1 positive to negative and 1 negative to positive). Patterns of biomarker expression in residual tumors were HER2 (+)/ER (–), 6 patients (22.2%); HER2 (+)/ER (+), 7 (25.9%); HER2 (–)/ER (+), 11 (40.7%); and triple negative (TN), 3 (11.1%). Recurrence was observed in 8/27 (29.6%) non-pCR patients, and patterns of biomarker expression in residual tumors were HER2 (+)/ER (–), 3 patients; HER2 (+)/ER (+), 2; and HER2 (–)/ER (+), 3. In addition, 1 patient with a HER2 (+)/ER (+) tumor and 1 patient with a HER2 (−)/ER (+) tumor died. RFS and OS were not statistically different between patients classified based on ER and Ki67 expressions. However, in the 18 non-pCR patients with primary tumor HER2 score of 3+ (overexpression of HER2 protein), the 10 with HER2-positive residual tumors showed significantly lower RFS than the 8 with HER2-negative (p < 0.04).
Conclusions: Although this regimen achieved a high pCR rate in HER2-positive BC patients, about 40% still had residual tumors. In the present study, we found that positive HER2 expression seen in pre-NAC tumors became negative in 52% of residual tumors after NAC. Theses HER2-negative residual tumors might not respond well to trastuzumab therapy, and residual tumors remaining HER2 positive might show low or no response to trastuzumab therapy. Moreover, the prognosis seems worse for non-pCR patients with HER2-positive residual tumors. However, Ki67 was not a significant prognostic factor. Examining biomarker expression of residual tumors after NAC seems very important for deciding further adjuvant therapy.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-06.
Collapse
Affiliation(s)
- S Kurozumi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - H Takei
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Inoue
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - H Matsumoto
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - Y Hayashi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - J Ninomiya
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - K Kubo
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - M Tsuboi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - S Nagai
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - F Ookubo
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - H Oba
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - M Kurosumi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - J Horiguchi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| | - I Takeyoshi
- Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan
| |
Collapse
|
47
|
Ohshima M, Kanda H, Kubo K, Yonezumi-Hayashi A, Tateishi S, Yamamoto K. Characterization of 5C11-positive activated interferon-producing cells in patients with systemic lupus erythematosus. Lupus 2012; 22:44-51. [PMID: 23087259 DOI: 10.1177/0961203312463620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVE 5C11 antibody is a novel monoclonal antibody against human BST2 and can be used to detect activation of interferon-producing cells (IPCs). Activated IPCs, which produce large amounts of interferon-α (IFNα), are considered to play an important role in the pathogenesis of systemic lupus erythematosus (SLE). We investigated the characterization of 5C11-positive cells in patients with SLE. METHODS The proportions of 5C11-positive cells among blood dendritic cell antigen 2 (BDCA-2)-, CD3-, CD19- and CD14-positive cells in peripheral blood from SLE patients (SLE-PBMCs) and healthy controls (control-PBMCs) were analyzed by flow cytometry. The effect of 5C11 antibody on IFNα production from SLE-PBMCs under stimulation with cytosine-phosphate-guanosine (CpG2216, bacterial oligonucleotide motif) was also examined by enzyme-linked immunosorbent assay (ELISA). RESULTS The proportions of 5C11-positive cells among BDCA-2-, CD3- and CD19-, but not CD14-positive cells in SLE-PBMCs were significantly increased compared to those in control-PBMCs (p < 0.0001, all). Especially, the number of 5C11-positive cells among BDCA-2-positive cells was significantly increased in SLE-PBMCs by about six-fold compared to that in control-PBMCs (p < 0.0001). 5C11 antibody inhibited IFNα production by SLE-PBMCs induced by CpG and the inhibition rates was 27% (p < 0.001). CONCLUSION SLE patients had a significantly higher proportion of 5C11-positive cells among CD3 and CD19 cells, and especially BDCA-2 positive cells. The ability of 5C11 antibody to inhibit IFNα production from SLE-PBMCs warrants further investigation for its possible clinical application for the treatment of SLE.
Collapse
Affiliation(s)
- M Ohshima
- Department of Allergy and Rheumatology, University of Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
48
|
Kubo K, Okanoya K, Kawai N. An apology suppresses the approach motivation but not the emotional component of physiological and psychological anger. Int J Psychophysiol 2012. [DOI: 10.1016/j.ijpsycho.2012.06.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Yamamoto H, Yasuo M, Ito M, Yokoyama T, Hamano H, Uehara T, Kawakami S, Kubo K. Clinical features of central airway involvement in autoimmune pancreatitis. Eur Respir J 2012; 38:1233-6. [PMID: 22045794 DOI: 10.1183/09031936.00017611] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
50
|
Tanabe H, Sawada A, Takayama K, Sueoka M, Kubo K, Itoh T, Nakai T, Furukawa H, Matsuo Y, Kokubo M. Evaluation of setup accuracy for Stereotactic Body Radiation Therapy in MHI-TM2000 System (Vero). Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|